Clinical efficacy of kantaka panchamoola in Shukra Dushti
- Conditions
- Health Condition 1: N461- OligospermiaHealth Condition 2: N468- Other male infertility
- Registration Number
- CTRI/2022/03/041228
- Lead Sponsor
- Ayurvedic and Unani Tibbia College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 64
a) Male Patients between the age group of 21-50 years of age.
b) Willing and able to participate in the study for 90 days.
c) Patients suffering from semen disorders over the past 6 months or more.
d) Patients with History of Infertility for the past 3 years.
f) Patients with lack of libido / sexual desire/ Impotence/ Erectile Dysfunction.
g) Patients with Difficulty in ejaculation of semen.
h) Patients ejaculating little quantity of semen after painful coitus.
a) Men with a total sperm concentration of < 5â??million/mL
b) Patients having a history of congenital deformity in genitals.
c) Patients with evidence of Malignancy.
d) Patients having any type of surgery of genitals.
e) Known case of serious hepatic, cardiac or kidney diseases.
f) Patients having history of Chronic Fever.
g) Patient having any sexual transmitted diseases.
h) Patients on prolonged medication with corticosteroids, antidepressants,
anticholinergics, immunosuppressant, etc. or any other drugs that may have an
influence on the outcome of the study.
i) Patients with poorly controlled hypertension (systolic >140 and diastolic >90 mm of
Hg) despite of antihypertensive agents.
j) Hypersensitivity to any of the trial drugs or their ingredients.
k) Patients who have completed participation in any other clinical trial drugs or their
ingredients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The Expected Primary End point is improvement in the semen parameters. <br/ ><br>levels from baseline (Day 1) after 90 days of therapyTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method The Expected secondary outcome is the safety and efficacy of the therapy under investigation. <br/ ><br>Safety will be assessed based on the adverse events recorded during the studyTimepoint: 3 months